Prometic Presents New Data on PBI-4050 and its Mechanism of Action on Kidney Fibrosis at the 56th ERA/EDTA Congress

Published: 14/06/2019
Prometic Presents New Data on PBI-4050 and its Mechanism of Action on Kidney Fibrosis at the 56th ERA/EDTA Congress
Source: WWW.PRNEWSWIRE.COM

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, June 14, 2019 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic), a biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney...

Read more
Related news
Comment
FACEBOOK